FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Washington, D.C. 20549

**OMB APPROVAL** 3235-0287 Estimated average burden hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  YANG MICHAEL J.						2. Issuer Name and Ticker or Trading Symbol Pacira BioSciences, Inc. [ PCRX ]									ationship k all app Direc	,	ng Pers	son(s) to Is	
(Last)	ast) (First) (Middle)				3. Date of Earliest Transaction (Month/Day/Year) 08/14/2024									Office belov	er (give title v)		Other (s below)	specify	
C/O PACIRA BIOSCIENCES, INC. 5401 WEST KENNEDY BOULEVARD, SUITE 890						4. If Amendment, Date of Original Filed (Month/Day/Year)								6. Indi Line)	Form filed by More than One Reporting				
(Street) TAMPA FL 33609				Rule 10b5-1(c) Transaction Indication															
(City) (State) (Zip)							Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.												nded to
		Table	I - No	n-Deriva	tive S	ecui	rities	Acq	uired,	Dis	oosed of	, or E	Bene	ficially	y Own	ed			
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da						Execution			3. Transa Code (1 8)							ties cially Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership
									Code	v	Amount	(A) (D)	or F	rice	Report Transa (Instr. 3	ed ction(s) 3 and 4)			(Instr. 4)
Common Stock 08/14/2						2024		P		2,000	A \$12		\$12.9	7,230		D			
		Tal									osed of, o				Owne	d			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)		4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisab Expiration Date (Month/Day/Year)		te	and 7. Title and Amount of Securities Underlying Derivative Security (In 3 and 4)		De Se (In	Price of rivative curity str. 5)	9. Number derivative Securities Beneficially Owned Following Reported Transaction (Instr. 4)	ily C	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
					Code	v (A)		(D)	Date Exercisable		Expiration Date	Title	Amor or Numi of Share	ber					

**Explanation of Responses:** 

Remarks:

/s/ Kristen Williams, Attorney-in-Fact

08/14/2024

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.